QA108 Phase III Study in Subjects With Intermediate AMD

Smilebiotek Zhuhai

Status and phase

Enrolling

Phase 3

Conditions

Intermediate Age-Related Macular Degeneration

Treatments

Drug: QA108 granules placebo

Drug: QA108 granules

Study type

Interventional

Funder types

Industry

Identifiers

NCT07189169

QA108-III

Details and patient eligibility

About

This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Enrollment

400 estimated patients

Sex

All

Ages

45 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The study eye meets the Western medicine diagnostic criteria for intermediate age-related macular degeneration;
Presence of at least one large drusen (diameter ≥125 μm) in the macular area of the fundus;
Consistent with the TCM diagnosis of type of Yang-hyperactivity due to Yin-deficiency;
Age 45-85 years (inclusive), regardless of gender;
The study eye has a BCVA of 88-34 letters (using the ETDRS chart, inclusive of threshold values), equivalent to a Snellen visual acuity of 20/20 to 20/200 (inclusive);
Voluntary participation in this clinical trial, with informed consent provided and an informed consent form signed

Exclusion criteria

The study eye is with concomitant eye disorders that may interfere with the observation of the trial as judged by the investigator, including pathological myopia, glaucoma, diabetic retinopathy, retinal vein occlusion, uveitis, retinal detachment, optic neuropathy (optic neuritis, atrophy, papilledema), and macular hole;
The study eye has an intraocular pressure (IOP) ≥ 25 mmHg;
Presence of geographic atrophy (GA) involving the foveal center in the study eye;
Previous ophthalmic surgery in the study eye: vitrectomy, macular translocation;
Aphakia (except pseudophakia) or posterior capsule rupture (except YAG laser posterior capsulotomy after IOL implantation at more than 1 month prior to screening) of the study eye;
Any intraocular surgery (excluding intravitreal injections) that may affect trial observations or imaging in the study eye within 3 months;
Cataract in the study eye that interferes with fundus examination or imaging;
Treatments received in the study eye within 3 months prior to screening, including macular laser photocoagulation and micropulse laser therapy;
The patient received relevant TCM treatment within 1 month prior to screening;
Active ocular infection in either eye that affects fundus examination or imaging;
The non-study eye has a BCVA of less than 19 ETDRS letters (not inclusive);
Known allergy to the therapeutic or diagnostic drug used in the study protocol, including the single drug components in the study drugs;
Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg after regular use of antihypertensive drugs);
Platelet count ≤100×10⁹/L (unless follow-up results are normal), or any of the following exceeding 1.5 times the upper limit of normal (ULN): total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), or serum creatinine (Cr);
Pregnant women, women who are breastfeeding, those who plan for pregnancy in the next six months, or those who are unwilling to take effective birth controls during the study course and until six months after drug withdrawal;
Any uncontrollable clinical disorder prior to the start of treatment, such as severe psychiatric, neurological, respiratory, immunological, hematological, and cardiac system diseases, and malignant tumors;
Subjects who have participated in other clinical trials within 3 months prior to this trial;
Patients who are unsuitable for participating at the discretion of the investigator.